KRAZATI became the first KRAS inhibitor to get the regulatory nod for the treatment of KRAS G12C–mutant locally advanced or metastatic colorectal cancer. When it comes to biomarker-specific ...
At ASCO, Eli Lilly, Genfleet Therapeutics and InxMed all presented new clinical data on KRAS G12C inhibitors in non-small cell lung cancer (NSCLC), going after the same mutation and indication as ...
Under the terms of the deal, Jazz will acquire Redx’s KRAS inhibitor programme outright ... FDA-approved as second-line therapies for KRAS G12C-mutated non-small cell lung cancer (NSCLC ...
The researchers combined a newly identified KRAS G12C inhibitor, with a compound that blocks a protein called SHP2, which inhibits cancer cells and can also activate tumor immunity. These two ...
Also, Roche’s KRAS G12C inhibitor divarasab has shown a 62% ORR when combined with Erbitux in a phase 1 trial. The data readout for Cardiff’s CRDF-004 trial is imminent now. The trial is still ...
Alterome Therapeutics, Inc., a biopharmaceutical company pioneering the development of next generation, small molecule targeted therapies for the treatment of cancer, today announced that data from ...
REDWOOD CITY, CA, USA I3, 2024 I Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced encouraging ...
Non-small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as ...
ALTA3263 demonstrates preclinical antitumor activity in the most common KRAS mutant cancers IND-enabling studies are ongoing to support clinical trial initiation in early 2025 Alterome Therapeutics ...